| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-148 |
Sentence |
denotes |
The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model. |
| T1 |
0-148 |
Sentence |
denotes |
The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model. |
| T2 |
149-160 |
Sentence |
denotes |
BACKGROUND: |
| T2 |
149-160 |
Sentence |
denotes |
BACKGROUND: |
| T3 |
161-291 |
Sentence |
denotes |
In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate inflammation. |
| T3 |
161-291 |
Sentence |
denotes |
In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate inflammation. |
| T4 |
292-506 |
Sentence |
denotes |
In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects. |
| T4 |
292-506 |
Sentence |
denotes |
In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects. |
| T5 |
507-515 |
Sentence |
denotes |
METHODS: |
| T5 |
507-515 |
Sentence |
denotes |
METHODS: |
| T6 |
516-740 |
Sentence |
denotes |
Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h. |
| T6 |
516-740 |
Sentence |
denotes |
Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h. |
| T7 |
741-812 |
Sentence |
denotes |
Oral mucosal biopsies were taken before surgery and 48 h after surgery. |
| T7 |
741-812 |
Sentence |
denotes |
Oral mucosal biopsies were taken before surgery and 48 h after surgery. |
| T8 |
813-933 |
Sentence |
denotes |
After extraction, a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 (TXB2) measurements. |
| T8 |
813-933 |
Sentence |
denotes |
After extraction, a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 (TXB2) measurements. |
| T9 |
934-942 |
Sentence |
denotes |
RESULTS: |
| T9 |
934-942 |
Sentence |
denotes |
RESULTS: |
| T10 |
943-1113 |
Sentence |
denotes |
The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. |
| T10 |
943-1113 |
Sentence |
denotes |
The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. |
| T11 |
1114-1295 |
Sentence |
denotes |
However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups. |
| T11 |
1114-1295 |
Sentence |
denotes |
However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups. |
| T12 |
1296-1417 |
Sentence |
denotes |
Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group. |
| T12 |
1296-1417 |
Sentence |
denotes |
Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group. |
| T13 |
1418-1584 |
Sentence |
denotes |
Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1. |
| T13 |
1418-1584 |
Sentence |
denotes |
Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1. |
| T14 |
1585-1597 |
Sentence |
denotes |
CONCLUSIONS: |
| T14 |
1585-1597 |
Sentence |
denotes |
CONCLUSIONS: |
| T15 |
1598-1793 |
Sentence |
denotes |
These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates. |
| T15 |
1598-1793 |
Sentence |
denotes |
These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates. |